SGLT2 inhibitors reduce podocyte lipotoxicity and improve kidney function in experimental Alport syndrome through a mechanism that involves a switch from the utilization of glucose to fatty acids as an energy substrate in podocytes.

Targeting the interaction between the kidneys and brain may increase the efficiency of SGLT2 inhibitors to better manage type 2 diabetes.

A calcium transient measurement system utilizing human induced pluripotent stem cell-derived cardiomyocytes reveals the detrimental impact of inflammatory cytokines on cardiomyocyte relaxation and displays the potential of drugs to reverse these defects.

Monounsaturated fatty acids protect against DKD by enhancing membrane fluidity and decreasing ER lipid bilayer stress in renal proximal tubules.

Human metabolism-focused screens reveal clinically promising interventional strategies and repurposing targets to treat COVID-19.

An unbiased approach unveils a non-canonical substrate of the known transporters, highlighting the mechanism behind the use of D-serine as a kidney biomarker.

In lung adenocarcinoma, deleting one glucose transporter, whether it is Glut1 or Glut3 is insufficient, whereas their dual deletion reduces tumor growth.

Zebrafish insulin mutants serve as an innovative platform to identify novel mechanisms regulating glucose homeostasis.

Anti-asprosin monoclonal antibodies, a promising pharmacotherapy for the treatment of metabolic syndrome-associated hyperglycemia, obesity, and dyslipidemia.

Animal studies of fatty liver disease over-estimate the benefit of drugs due to publication bias and are confounded by off-target weight loss, illustrating the challenge of successful translational across species.